NCT05094336, a first-in-human (FIH), open-label, multicenter phase I/II trial, is enrolling patients with MTAP-null NSCLC to evaluate the safety, tolerability, PK, PD, and efficacy of AMG 193. This evidence concerns the gene MTAP and non-small cell lung carcinoma.